Page 68 - Read Online

Yonemura et al. J Cancer Metastasis Treat 2022;8:43 Journal of Cancer
DOI: 10.20517/2394-4722.2022.49
Metastasis and Treatment

Review Open Access

Peritoneal mesothelioma

2
2
3
2
2
Yutaka Yonemura 1,2,3 , Haruaki Ishibashi , Akiyoshi Mizumoto , Takuji Fujita , Yang Liu , Satoshi Wakama ,
2
2
3
2
2
Syouzou Sako , Nobuyuki Takao , Toshiyuki Kitai , Kanji Katayama , Yasuyuki Kamada , Keizou
4
Taniguchi , Daisuke Fujimoto 4
1
Asian School of Peritoneal Surface Malignancy Treatment, Kyoto City, Kyoto 600-8189 Japan.
2
Department of Regional Cancer Therapy, Peritoneal Dissemination Center, Kishiwada Tokushukai Hospital, Kishiwada City,
Oosaka 596-8522 Japan.
3
Department of Regional Cancer Therapy, Peritoneal Dissemination Center, Kusatsu General Hospital, Kusatsu City,
Shiga 525-8585 Japan.
4
Department of Surgery, Mizonokuchi Hospital, Teikyo University, School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Correspondence to: Dr. Yutaka Yonemura, Representative of Asian School of Peritoneal Surface Malignancy Treatment,
Department of Regional Cancer Therapies, Peritoneal Surface Malignancy Treatment Center, Kishiwada Tokushukai Hospital,
Osaka 596-8522 Japan. E-mail: y.yonemura@coda.ocn.ne.jp
How to cite this article: Yonemura Y, Ishibashi H, Mizumoto A, Fujita T, Liu Y, Wakama S, Sako S, Takao N, Kitai T, Katayama K,
Kamada Y, Taniguchi K, Fujimoto D. Peritoneal mesothelioma. J Cancer Metastasis Treat 2022;8:43.
https://dx.doi.org/10.20517/2394-4722.2022.49
Received: 11 May 2022 First Decision: 24 May 2022 Revised: 1 Aug 2022 Accepted: 21 Sep 2022 Published: 28 Sep 2022
Academic Editor: Raja Flores Copy Editor: Fangling Lan Production Editor: Fangling Lan
Abstract
This review provides an overview of articles about peritoneal mesothelioma (PM) to analyze the effect of
treatment modalities on response rates, post-treatment side effects, morbidity and mortality, and survival. Median
survival in months following systemic chemotherapy (SC) ranged from 8.7 to 26.8 months. However, no patient
was reported to have survived for more than five years with SC alone. In contrast, comprehensive treatment that
included cytoreductive surgery (CRS) + perioperative chemotherapy (POC) showed a significantly longer median
survival time than SC alone. Additionally, CRS + POC demonstrated 10-year survival rates of 12%-35%.
Accordingly, CRS + POC is an innovative treatment that provides long-term survival in selected patients with PM.
Selection criteria are performance status (ECOG PS ≤ 1), the absence of extraperitoneal metastasis, PCI less than
cutoff levels (from < 10 to < 28), MIB-1 index (< 10), and histologic type (epithelioid type). Postoperative morbidity
and mortality rates after CRS + POC were significantly higher than with more conventional operations. Accordingly,
CRS and POC should be done at the specialized peritoneal surface malignancy centers.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.

www.jcmtjournal.com